Merck Biopharma Innovation Cup 2017

MerckMerck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent. It showcases Merck's deep commitment to leverage innovation, curiosity and collaboration. With more than 1,400 applications from 60 countries, this year's Biopharma Innovation Cup achieved a new record of popularity. Thirty-three participants worked hand in hand with experienced Merck researchers and managers in the biopharma field on developing business plans. For 6 days, bright minds came together at the Innovation Camp near Frankfurt, Germany, and jointly developed novel ideas into innovative project plans for drug discovery.

The winning team "Immuno-Oncology" inspired the audience with their outstanding project proposal on how to translate NK cell biology into a drug discovery project.

The team consisted of:

  • Alex Kertser (Weizmann Institute of Science, Israel)
  • Franklin Zhong (A*STAR, Singapore)
  • Kelly Moynihan (MIT, USA)
  • Patrik Andersson (Karolinska Institute, Sweden)
  • Simone Mori (The Scripps Research Institute, USA)
  • Arne Sutter (team coach)

As runner-up receiving €5,000, the team "Medicinal Chemistry" was chosen with an innovative proposal on DNA-encoded libraries.

The team consisted of:

  • Adam McCallum (Georgia Institute of Technology, USA)
  • Anna Rydzik (LMU Munich, Germany)
  • Josua Jordi (Harvard, USA)
  • Rüdiger Borrmann (ETH Zürich, Switzerland)
  • Wilian Cortopassi (UCSF, USA)
  • Henning Böttcher (team coach)

The initiative has won several innovation awards over the years, including the Edison Award 2017, Stevie Gold Award 2017, German Industry Innovation Award 2015 and the German Idea Award 2014. More detailed information on the Biopharma Innovation Cup can be found at Biopharma Open Innovation Portal.

"The Biopharma Innovation Cup is getting increasingly popular at innovation hotspots all over the world from year to year. We are happy to offer young talents this development opportunity," said Dr Ulrich Betz, Vice President of Innovation & Entrepreneurship Incubator at the Healthcare business of Merck and initiator and manager of the Innovation Cup.

On the occasion of their 350th anniversary in 2018, Merck will conduct a special anniversary edition of the Innovation Cup, covering topics in Life Science and Performance Materials in addition to Healthcare. Applications to participate in the 2018 edition of the cup can be submitted starting October 01, 2017, here: http://innovationcup.merckgroup.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...